|
||||||||||
|
||||||||||
|
||||||||||
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi |
||||||||||
|
|
|||||||||
1. Identity of the issuer or the underlying issuer |
E-THERAPEUTICS PLC |
|||||||||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||||||||
An acquisition or disposal of voting rights |
|
|||||||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||||||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||||||||
An event changing the breakdown of voting rights |
X |
|||||||||
Other (please specify): |
Acquisition of voting rights following placing. |
X |
||||||||
3. Full name of person(s) subject to the |
Octopus Investments Limited |
|||||||||
4. Full name of shareholder(s) |
|
|||||||||
5. Date of the transaction and date on |
01/03/2013 |
|||||||||
6. Date on which issuer notified: |
05/03/2013 |
|||||||||
7. Threshold(s) that is/are crossed or |
Below 5% |
|||||||||
8. Notified details: n/a |
||||||||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
||||||||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
||||||||||||
GB00B2823H99 |
8,753,908 |
8,753,908 |
n/a |
n/a |
11,097,658 |
|
11,097,658 |
|||||||||
|
||||||||||||||||
|
||||||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||
n/a |
n/a |
n/a |
n/a |
n/a |
||||||||||||
|
||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|||||||||||
n/a |
n/a |
n/a |
n/a |
n/a
|
Nominal |
Delta |
||||||||||
n/a
|
n/a
|
|||||||||||||||
|
||||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
11,097,658 |
4.22% |
|||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||||||||||||
|
||||||||||||
|
||||||||||||
Proxy Voting: |
||||||||||||
10. Name of the proxy holder: |
See 4 above. |
|||||||||||
11. Number of voting rights proxy holder will cease |
n/a |
|||||||||||
12. Date on which proxy holder will cease to hold |
n/a |
|||||||||||
|
||||||||||||
|
|
|||||||||||
14. Contact name: |
Tracey Spevack, Octopus Investments Ltd |
|||||||||||
15. Contact telephone number: |
020 7776 3195 |
|||||||||||